Canadian NeuroEndocrine Tumour Society

07/18/2025

CNETS is proud to announce the 2025 NET Research Grant Competition exclusively for CommNETs members. Grants of up to $22,500 are available for collaborative projects between Canada, Australia, and New Zealand focused on Neuroendocrine Tumors (NETs). This initiative aims to support innovative research that enhances patient care and understanding of NETs. Applications are open now until September 18, 2025. Don't miss this chance to advance NET research!

https://conta.cc/4lV4jKi

07/09/2025

Access to care and NET diagnosis isn’t always a smooth path—and we want to help change that.

💬 If you're a NET patient or caregiver anywhere in Canada, we want to hear from you. Your experience matters, and your voice can help improve care nationwide.

📢 Take the survey and help shape the future of NET support in Canada.

https://www.surveymonkey.com/r/ACCESSTONETCARE

06/25/2025

🧠 Help us improve mental health support for the NET community!

We're conducting a short, anonymous survey to better understand your experiences and needs.

Whether you're a patient, caregiver, or health care provider, your voice matters.

💬 It takes just 10 minutes — and your input will help shape programs, resources, and advocacy efforts that make a real difference.

📢 Share your perspective. Advocate for change.

https://www.surveymonkey.com/r/CNETSMHS

06/05/2025

06/02/2025

A team of researchers from the University of Iowa has unveiled concerns about the use of semaglutide, a widely prescribed GLP-1 receptor agonist for type 2 diabetes and obesity, in patients with neuroendocrine neoplasms (NENs).

While semaglutide has proven effective in managing blood sugar and promoting weight loss, its effects on certain rare cancer types warrant caution, the researchers note in their in-press article in the journal Surgery. Semaglutide may stimulate the growth of neuroendocrine cancers that express GLP-1 receptors, they found, shedding light on an unanticipated risk for some patients.

https://netrf.org/2024/12/17/research-reveals-potential-risks-of-popular-glp-1-medications-for-some-with-neuroendocrine-cancer/?fbclid=IwY2xjawKquRtleHRuA2FlbQIxMQBicmlkETFpY0Z4NEhpOWRPdHVmZ0Z1AR4Rn-zLpSF_0Tcks8Kh1YPthQgZZ_zEqacqKd5MhLJq2Nc4ZhCCWCcsiSDDmQ_aem_4G0guafufakQ9hSu1TMj1w

A team of researchers from the University of Iowa has unveiled concerns about the use of semaglutide, a widely prescribed GLP-1 receptor agonist for type 2 diabetes and obesity, in patients with neuroendocrine neoplasms (NENs). While semaglutide has proven effective in managing blood sugar and promo...

06/01/2025

The CNETS annual virtual fundraiser, HOOFING IT, is back from June 1st to September 30th, 2025! Join the Canadian neuroendocrine cancer community in our mission to raise $60,000 for vital NET cancer research. This engaging event allows participants to earn points through activities like walking, swimming, and cycling while making a difference. Together, we can support groundbreaking research and award grants to deserving projects across Canada. Join Team Zebra or donate today!

Email from CNETS June 1st to September 30th, 2025 CNETS annual summer-long virtual fundraiser is back! HOOFING IT FOR NEUROENDOCRINE CANCER RESEARCH From June 1st to September 30th, 2025, the Canadia

05/15/2025

2025 SCIENTIFIC & MEDICAL ADVISORY BOARD (SMAB)
The CNETS Board of Directors is thrilled to announce the members of the 2025 Scientific & Medical Advisory Board (SMAB). The SMAB provides strategic guidance on scientific and medical matters that advance CNETS’ mission.
https://conta.cc/4j1ZKw5

Email from CNETS 2025 SCIENTIFIC & MEDICAL ADVISORY BOARD (SMAB) The CNETS Board of Directors is thrilled to announce the members of the 2025 Scientific & Medical Advisory Board (SMAB). The SMAB provi

04/18/2025

CNETS proudly announces awarding five NET cancer research grants for 2024, including three named grants. This initiative supports innovative research to enhance the quality of life and treatment outcomes for Neuroendocrine cancer patients in Canada. Congratulations to the grant recipients whose work will significantly impact the future of NET cancer research.
https://conta.cc/3GedxBL

04/06/2025

Neuroendocrine cancer research can save lives!
The CNETS 2024 NET CANCER RESEARCH GRANT RECIPIENTS announcement is coming soon!

04/04/2025

Join us for:
CNETS 2025 NATIONAL NET PATIENT CONFERENCE
May 23 – 25, 2025
Alt Hotel University District CALGARY, ALBERTA

You can scan the QR code with your phone camera, go to the conference website for more information, and register.

04/01/2025

Bailey Daniels, a tireless advocate for neuroendocrine cancer research and patient support, has been posthumously awarded the King Charles III Coronation Medal in recognition of her extraordinary contributions to fundraising and advocacy. The award, commemorating the coronation of King Charles III as King of Canada, is given to individuals whose achievements have made a significant impact on the country.

Full story at: https://conta.cc/3FLfGF7

03/31/2025

Bailey Daniels, a tireless advocate for neuroendocrine cancer research and patient support, has been posthumously awarded the King Charles III Coronation Medal in recognition of her extraordinary contributions to fundraising and advocacy. The award, commemorating the coronation of King Charles III as King of Canada, is given to individuals whose achievements have made a significant impact on the country.

https://conta.cc/3QWz0l2

Email from CNETS Bailey Daniels Posthumously Honoured with King Charles III Coronation Medal for Advocacy in Neuroendocrine Cancer Research   Bailey Daniels, a tireless advocate for neuroendocrine can